arrow
A

Akshay Kharat

janssen scientific affairs, llc, horsham, pa, usahttps://orcid.org/0000-0002-1056-9466
H指数:10
被引数:256

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States

美国接受1至3线前期治疗(包括蛋白酶体抑制剂和免疫调节药物)并曾使用后停用来那度胺的多发性骨髓瘤患者的医疗资源利用和费用

2025-11-190
OAAI
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database

真实世界中接受1-3线前期治疗的患者复发/难治性多发性骨髓瘤的治疗模式与结局:Optum数据库

2025-07-280
OAAI
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

来那度胺难治性多发性骨髓瘤患者特征及结局:达雷木单抗临床试验个体患者水平数据分析

2025-01-010
PRE